Natalizumab Induction and Maintenance Therapy for Crohn's Disease

J. Sandborn, William; Colombel, Jean‐Frédéric; Enns, Roberts; G. Feagan, Brian; B. Hanauer, Stephen; C. Lawrance, Ian; Panaccione, Remo; E. Sanders, Martin; Schreiber, Stefan; R. Targan, Stephan; van Deventer, Sander; Goldblum, Ronald; Despain, Darrin; S. Hogge, Gary; Rutgeerts, Paul

doi:10.1056/nejmoa043335

Public

Natalizumab Induction and Maintenance Therapy for Crohn's Disease

Published in New England Journal of Medicine • Nov 2, 2005

Authors:

William J. Sandborn

Jean‐Frédéric Colombel

Roberts Enns

Abstract

BACKGROUND: Natalizumab, a humanized monoclonal antibody against alpha4 integrin, inhibits leukocyte adhesion and migration into inflamed tissue. METHODS: We conducted two controlled trials to evaluate natalizumab as induction and maintenance therapy in patients with active Crohn's disease. In the f...

Subject

Natalizumab

Medicine

Placebo

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!